Cardioprotective Effects of Chronic Release Formulations of Subcutaneous Implants of Carvedilol in Spontaneously Hypertensive Rats

Background: In our laboratory, we have developed subcutaneous implants of carvedilol capable of maintaining stable concentrations of the β-blocker during 3 weeks. Objective: The aim of this study was to evaluate the in vivo release and the cardioprotective efficacy of subcutaneous implants of carvedilol developed with poly-epsilon-caprolactone (PCL) and Soluplus (SP) polymers in spontaneously hypertensive rats (SHR). Methods: Twelve spontaneously hypertensive male rats (250-300 g) underwent placement of subcutaneous implant of PCL:SP 100:50 mg (control group, n = 6) or carvedilol:PCL:SP (100mg:100mg:50mg) (carvedilol group, n = 6), every 3 weeks. The plasma profile of each implant and its effect on systolic blood pressure (SBP) was evaluated for 62 days. At the end of treatment, echocardiographic parameters were determined, and direct SBP and direct mean arterial pressure (MAP) were measured. Results: The group that received the implant containing 100 mg of carvedilol presented plasma concentrations of the drug in the range of 100- 500 ng/mL throughout 62 days of treatment, after which the SBP was 20 mmHg lower than in the control group (217±3 mm Hg vs. 237 ± 6 mm Hg; p <0.05). Direct SBP and MAP were significantly lower in the treated group than in the control group. The implant loaded with carvedilol 100 mg reduced short-term blood pressure variability (BPV) in SHR compared with the control group. Echocardiographic parameters as left ventricular ejection fraction (LVEF), shortening fraction and E/A ratio were significantly greater in treated rats. Left ventricular weight was lower in the rats with carvedilol implant. Conclusion: Implants containing CAR/PCL/SP (100:100:50) mg provide therapeutic and stable plasma levels of carvedilol during treatment, which correlate with a significant and sustained decrease in indirect BP values. Treatment with carvedilol implants attenuated direct BP values and blood pressure variability in SHR. Treatment with implant produced cardioprotective effects evidenced in the echocardiogram by a reduction in left ventricular hypertrophy.

[1]  M. Allo,et al.  Desarrollo de implantes subcutáneos de liberación controlada de Carvedilol para la reducción sostenida de la presión arterial en modelos experimentales de hipertensión arterial , 2020 .

[2]  G. Parati,et al.  Reduction of blood pressure variability: an additional protective cardiovascular effect of vasodilating beta-blockers? , 2020, Journal of hypertension.

[3]  D. Chiappetta,et al.  Effects of third-generation β-blockers, atenolol or amlodipine on blood pressure variability and target organ damage in spontaneously hypertensive rats. , 2020, Journal of hypertension.

[4]  N. Jones,et al.  The 2018 ESC/ESH hypertension guideline and the 2019 NICE hypertension guideline, how and why they differ. , 2019, European heart journal.

[5]  D. Jain,et al.  Enhancement of oral bioavailability of poorly water soluble carvedilol by chitosan nanoparticles: Optimization and pharmacokinetic study. , 2019, International journal of biological macromolecules.

[6]  K. Hosny,et al.  Optimization of carvedilol solid lipid nanoparticles: An approach to control the release and enhance the oral bioavailability on rabbits , 2018, PloS one.

[7]  G. Parati,et al.  Morning blood pressure surge: pathophysiology, clinical relevance and therapeutic aspects , 2018, Integrated blood pressure control.

[8]  K. Kario,et al.  Blood pressure monitoring: theory and practice. European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability Teaching Course Proceedings. , 2017, Blood pressure monitoring.

[9]  C. Hocht,et al.  What is the Real Efficacy of Beta-Blockers for the Treatment of Essential Hypertension? , 2017, Current pharmaceutical design.

[10]  D. Chiappetta,et al.  Novel carvedilol paediatric nanomicelle formulation: in‐vitro characterization and in‐vivo evaluation , 2017, The Journal of pharmacy and pharmacology.

[11]  D. Chiappetta,et al.  Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability. , 2017, Journal of the American Society of Hypertension : JASH.

[12]  Guido Grassi,et al.  Evidence for a critical role of the sympathetic nervous system in hypertension. , 2016, Journal of the American Society of Hypertension : JASH.

[13]  G. Parati,et al.  Blood Pressure Variability: Assessment, Predictive Value, and Potential as a Therapeutic Target , 2015, Current Hypertension Reports.

[14]  Gavin W K Wong,et al.  First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. , 2015, The Cochrane database of systematic reviews.

[15]  Claus-Michael Lehr,et al.  Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  J. Flack,et al.  Benefits of once-daily therapies in the treatment of hypertension , 2011, Vascular health and risk management.

[17]  M. Boccia,et al.  In vitro/in vivo characterization of melt-molded gabapentin-loaded poly(epsilon-caprolactone) implants for sustained release in animal studies. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[18]  P. Gosse,et al.  The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials , 2007, Blood pressure monitoring.

[19]  D. Brooks,et al.  Antioxidant activity of carvedilol in cardiovascular disease , 2007, Journal of hypertension.

[20]  D. Su,et al.  Reduction of blood pressure variability: a new strategy for the treatment of hypertension. , 2005, Trends in pharmacological sciences.

[21]  U. Jana,et al.  PREPARATION AND PHYSICO-CHEMICAL CHARACTERIZATION OF CARVEDILOL-EUDRAGIT , 2018 .

[22]  W. Elliott.  Prevention of Cardiovascular Events With an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required Versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Tri , 2006 .

[23]  F. Zacharias.  Beta blockers in hypertension. , 1973, Bruxelles medical.